Navigation Links
Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
Date:5/13/2009

euticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic products in the U.S. market. They include: BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) and REPRONEX(R) (menotropins for injection, USP), Novarel(R) (chorionic gonadotropin for injection, USP), ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg, PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, DEGARELIX for injection and EUFLEXXA(R) (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For complete prescribing information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

* Derived through bacterial fermentation

(1) Data on File, Ferring Pharmaceuticals

(2) Altman RD, Rosen JE. Six-month safety and efficacy of non-avian intra-articular hyaluronan in knee osteoarthritis (OA).

(3) Schiavinato A, Finesso M, Cortivo R, & Abatangelo G (2002). Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp Rheumatol 20, 445-454.

(4) Goomer RS, Leslie K, Maris T, & Amiel D (2005). Native hyaluronan produces less hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res 239-245.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Lazarus Effect, a medical device company focused ... facilitate removal of blood clots, announced today that ... issued a new patent (U.S. Patent Number 8,795,305) ... TM and ReCover TM devices. ... stent-retriever (stentriever) with an integrated, novel, cover-based protection ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
...  Medtronic, Inc, one of the world,s largest medical device ... U.S. Department of Justice (DOJ), the Office of the ... Services, and four relators in a qui tam suit ... in the U.S., including pacemakers and implantable cardioverter defibrillators ...
... A three-drug combination treatment for the blood cancer multiple myeloma ... patients, according to a multi-center study led by Andrzej ... the multiple myeloma program at the University of Chicago Medical ... of the phase I-II study on Dec. 12, 2011, ...
Cached Medicine Technology:Settlement Announced in Medtronic Qui Tam Case 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 3
(Date:7/24/2014)... for head and neck cancer (HNC). Evidence suggests certain cancers ... of HNC in patients with DM has not been well ... common type of cancer. It accounts for about 6 percent ... cases and 350,000 cancer deaths worldwide each year. , The ... the risk of HNC in patients with DM. The authors ...
(Date:7/24/2014)... This year the Walk to End ... Jackson National Life, will be held on Saturday, September 20 ... Kids Fun Run at 7:50 am, the untimed 5k Run ... , “The Walk to End Alzheimer’s unites the entire community ... fight against this devastating disease, “stated Linda Mitchell, CEO and ...
(Date:7/24/2014)... two or more equally positive outcomes experience paradoxical ... activity in different regions of the brain, according ... research scholar at the Princeton Neuroscience Institute at ... people rated the desirability of more than 300 ... at images of paired products with different or ...
(Date:7/24/2014)... Memantine was initially developed by Merz to ... under the brand name Akatinol; it was later licensed to ... in the USA to Forest Labs as Namenda. Lundbeck reported ... In the US, Forest reported Namenda sales of USD 1.5 ... Australia and the European region has increased the competition from ...
(Date:7/24/2014)... at Carnegie Mellon University, working with high-throughput data ... National Laboratory, have devised a computational method to ... breast cells turn malignant and as they respond ... analyzing how genes interact with each other in ... today by the online journal PLOS Computational ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... ... undergoing leg amputation and detect heart disease earlier if diagnosis and treatment ... legs) were given higher priority by the NHS and there was better ... and Wales, the majority of which are caused by PAD, but there ...
... - Breast cancer patients with early stage disease that has ... radiation after mastectomy, because of the low present-day risk of ... could one day change the course of treatment for thousands ... University of Texas M. D. Anderson Cancer. The research, ...
... ... Sayer looked around for a good, reliable manufacturer for her award-winning cloth diapers, she did ... manufacturing facility, she also discovered a great way for her company to support its community ... Calgary, Alberta, Canada (PRWEB) ...
... may be the culprits, researchers suggest, , FRIDAY, March 5 ... red meat is a risk factor for heart disease, but ... meat -- not unprocessed red meat -- that increases the ... "processed meat" refers to any meat preserved by smoking, curing ...
... ... ... , ... , , , , ...
... ... ... ... ...
Cached Medicine News:Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 2Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 3Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 2Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 3Health News:Ecobumz Diapers are Going Green While Investing in its Own Community and Employing Women Looking to Enter or Re-enter the Workplace 2Health News:Processed Meat May Harm the Heart 2Health News:Processed Meat May Harm the Heart 3Health News:Processed Meat May Harm the Heart 4Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 2Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 3Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 2Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 3
Jewelers Forceps, delicate, straight....
Forceps, pointed, short jaws, suitable for epilation....
Cilia Forceps, slanted jaws, gold plated....
Accurate implant size. Polyoxymethylene (POM)....
Medicine Products: